利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

121 条记录 (耗时 0.028 秒)

    Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia
    3.
    发明公开
    Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia 审中-公开

    公开(公告)号：US20230160908A1

    公开(公告)日：2023-05-25

    申请号：US17929524

    申请日：2022-09-02

    申请人： The Trustees of the University of Pennsylvania

    发明人： Mark I. Greene ,  Douglas B. Cines ,  Zheng Cai ,  Zhiqiang Zhu

    IPC分类号： G01N33/68 ,  C07K16/24 ,  G01N33/86 ,  A61K39/395 ,  A61K38/19 ,  C07K14/52

    CPC分类号： G01N33/6863 ,  C07K16/24 ,  G01N33/86 ,  A61K39/3955 ,  A61K38/195 ,  C07K14/522 ,  G01N2333/522 ,  G01N2400/40 ,  G01N2800/222 ,  G01N2800/50 ,  G01N2800/52 ,  A61K2039/505

    摘要： The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants. The present invention also provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.

    Methods for measuring platelet reactivity of individuals treated with drug eluting stents
    5.
    发明授权
    Methods for measuring platelet reactivity of individuals treated with drug eluting stents 有权
    用药物洗脱支架治疗个体血小板反应性的方法

    公开(公告)号：US09506938B2

    公开(公告)日：2016-11-29

    申请号：US12598581

    申请日：2008-05-01

    申请人： Barry Coller ,  Dennis Durbin

    发明人： Barry Coller ,  Dennis Durbin

    IPC分类号： G01N33/86

    CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

    摘要： A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

    摘要翻译： 提供了用于测量用药物洗脱支架（DES）处理的个体中血小板反应性抑制的方法。 首先，从用DES和P2Y12拮抗剂处理的个体获得血液样品。 然后将血液样品与包含附着的GPIIb / IIIa受体配体，二磷酸腺苷（ADP）和前列腺素E1（PGE1）的颗粒混合。 将混合物在适合于凝集颗粒的条件下孵育，并在混合物中评估血小板介导的凝集。 凝集的不存在或减少表明用DES处理的个体降低了血小板反应性。 还提供了一种用于测量P2Y12受体拮抗剂抑制血小板聚集的试剂盒，其包括固定在颗粒上的GPIIb / IIIa受体配体，二磷酸腺苷（ADP），前列腺素E1（PGE1），抗凝血剂和缓冲液，以维持 抗凝血液适合血小板聚集。

    RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE
    6.
    发明申请
    RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE 审中-公开
    重组平板胶原蛋白受体GLYCOPROTEIN VI及其药物用途

    公开(公告)号：US20160207976A1

    公开(公告)日：2016-07-21

    申请号：US15064157

    申请日：2016-03-08

    申请人： Sanofi-Aventis Deutschland GmbH

    发明人： Kenneth CLEMESTON

    IPC分类号： C07K14/745 ,  G01N33/86 ,  C07K16/28

    CPC分类号： C07K14/745 ,  A61K38/00 ,  C07K14/70503 ,  C07K14/755 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/20 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/86 ,  G01N2015/0084 ,  G01N2333/4728 ,  G01N2333/78 ,  G01N2500/02 ,  G01N2800/222

    摘要： The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.

    摘要翻译： 本发明涉及糖蛋白VI（GPVI），其分离，纯化和重组生产方法。 特别地，本发明涉及GPVI，优选重组GPVI在治疗直接或间接与凝血障碍如血栓形成和心血管疾病相关联的病症和病理事件中的用途。 细胞外重组蛋白还可用于建立筛选试验以找到膜结合的GPVI的潜在抑制剂，以便分别抑制凝血细胞和血小板与胶原的结合。 GPVI的变化可用于监测血小板年龄和暴露于血栓和心血管疾病。

    BLOOD ANALYZER
    8.
    发明申请
    BLOOD ANALYZER 审中-公开
    血液分析仪

    公开(公告)号：US20150276720A1

    公开(公告)日：2015-10-01

    申请号：US14664997

    申请日：2015-03-23

    申请人： SYSMEX CORPORATION

    发明人： Masaki ABE ,  Tomohiro TSUJI

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5094 ,  G01N15/1459 ,  G01N33/492 ,  G01N33/56972 ,  G01N33/721 ,  G01N33/80 ,  G01N2800/222 ,  G01N2800/224

    摘要： A blood analyzer is provided that comprises: a measurement unit that measures a blood sample and outputs measurement data, a information processing unit that comprises a processor and a memory that stores a program to be executed by the processor to: analyze the measurement data outputted from the measurement unit, generate analysis data on each of blood cell types including red blood cells, white blood cells, and platelets, and generate support information for discriminating a cause of reduction in the number of blood cells of a predetermined type among the blood cell types from the analysis data comprising first analysis data on the predetermined blood cell type and second analysis data on a blood cell type other than the predetermined blood cell type, and an output unit that outputs the support information.

    摘要翻译： 本发明提供一种血液分析装置，其特征在于，包括：测量血液样本并输出测定数据的测定单元，包含处理器和存储由所述处理器执行的程序的存储器的信息处理单元，分析从 测量单元，生成包括红​​细胞，白血细胞和血小板在内的每种血细胞类型的分析数据，并产生用于鉴别血细胞类型中预定类型的血细胞数减少的原因的支持信息 从包括关于预定血细胞类型的第一分析数据和关于除了预定血细胞类型以外的血细胞类型的第二分析数据的分析数据和输出支持信息的输出单元。

    Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin, such as heparin-induced thrombocytopenia
    9.
    发明授权
    Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin, such as heparin-induced thrombocytopenia 有权
    用于检测肝素依赖性抗体的方法和试剂盒以及肝素加强的免疫或自身免疫病理学的诊断，例如肝素诱导的血小板减少症

    公开(公告)号：US09097731B2

    公开(公告)日：2015-08-04

    申请号：US12305224

    申请日：2007-06-25

    申请人： Jean Amiral ,  Anne-Marie Vissac

    发明人： Jean Amiral ,  Anne-Marie Vissac

    IPC分类号： G01N33/543 ,  G01N33/86

    CPC分类号： G01N33/86 ,  G01N2400/40 ,  G01N2800/222

    摘要： A method for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by a heparin substance, such as thrombocytopenia induced by heparin (HIT type II) as inducer drug. The method includes the steps of reacting at least one substance with high affinity for a heparin substance (SFA), with at least one heparin substance (SH) so as to form a substance with high affinity for heparin-heparin substance (SFA-SH) complex. The heparin substance is adapted to bind other substances with affinity for heparin and with at least one potential antigenic substance capable of reacting with the heparin substance, forming a (Ag-SH) complex. The method further includes the steps of testing a patient's plasma or serum potentially containing an anti(Ag-SH) antibody after administration of the heparin substance and revealing the resulting (Ag-SH)-anti(Ag-SH) complex produced.

    摘要翻译： 用于检测肝素依赖性抗体的方法和由肝素物质增强的免疫或自身免疫病理学的诊断，例如由肝素诱导的血小板减少症（HIT II型）作为诱导剂药物。 该方法包括使至少一种肝素物质（SFA）与至少一种肝素物质（SH）反应至少一种对肝素物质（SFA）具有高亲和力的物质以形成对肝素 - 肝素物质（SFA-SH）具有高亲和力的物质的步骤， 复杂。 肝素物质适用于与肝素具有亲合力的其他物质和能够与肝素物质反应的至少一种潜在的抗原物质，形成（Ag-SH）复合物。 该方法还包括以下步骤：在施用肝素物质之后测试可能含有抗（Ag-SH）抗体的患者血浆或血清，并显示产生的所得（Ag-SH）-anti（Ag-SH）复合物。